中国医院用药评价与分析2025，Vol.25Issue(2)：200-206,7.DOI:10.14009/j.issn.1672-2124.2025.02.016
地舒单抗治疗骨质疏松的快速卫生技术评估
Rapid Health Technical Evaluation of Disumab in the Treatment of Osteoporosis
摘要
Abstract
OBJECTIVE:To evaluate the efficacy,safety and economy of desumab in the treatment of osteoporosis by rapid health technology(HTA),so as to provide evidence-based evidence for clinical treatment.METHODS:PubMed,Embase,the Cochrane Library,CNKI,Wanfang Data,VIP,SinoMed and related HTA websites and databases were retrieved to collect high-quality clinical evidence and pharmacoeconomic evaluation literature of desumab in the treatment of osteoporosis(the intervention group were treated with desumab,while the control group received zoledronic acid and supportive treatment).The retrieval time was from the establishment of the database to Aug.30th,2024.After literature screening,data extraction and quality evaluation of included studies were conducted by two researchers,the results were qualitatively described and analyzed.RESULTS:A total of 27 literature were enrolled,including 2 HTA reports,12 systematic reviews/Meta-analyses,and 13 pharmacoeconomic studies.In terms of efficacy,disumab can significantly improve the bone mineral density of lumbar spine,hip and femoral neck,and reduce the level of bone markers,and the effect of combination is better than that of single drug.In terms of safety,disumab mainly caused ear,nose,throat and gastrointestinal tract infections,the overall incidence was low,and the cardiovascular benefits were more beneficial in elderly patients.Economic studies showed that desumab had a cost-benefit advantage in the treatment of primary osteoporosis.CONCLUSIONS:Desumab has certain efficacy and safety in the treatment of osteoporosis,yet high-quality,large sample and multi-center studies are needed to further reveal the efficacy,safety and economy.关键词
地舒单抗/骨质疏松/快速卫生技术评估Key words
Desumab/Osteoporosis/Rapid health technology assessment分类
医药卫生引用本文复制引用
焦敏,龚福恺,于鲁海,吴建华..地舒单抗治疗骨质疏松的快速卫生技术评估[J].中国医院用药评价与分析,2025,25(2):200-206,7.基金项目
2022 白求恩·求索-药学科研能力建设项目(No.Z04JKM2021005) （No.Z04JKM2021005）
